Novo Nordisk’s (NVO) U.S.-listed shares are rising 4% in premarket buying and selling Wednesday after the Ozempic and Wegovy maker’s better-than-estimated quarterly outcomes offset slower 2025 gross sales progress projections amid «intensifying competitors.»

The maker of blockbuster weight-loss medicine Ozempic and Wegovy reported fourth-quarter gross sales jumped 30% year-over-year to 85.68 billion Danish kroner ($11.97 billion), above the DKK80.62 billion estimate of analysts compiled by Seen Alpha. Novo Nordisk’s revenue of DKK28.23 billion additionally topped estimates.

Wegovy gross sales soared 107% at fixed alternate charges to DKK19.87 billion, slightly below estimates. Ozempic gross sales rose 12% to DKK33.85 billion, above expectations.

Novo Nordisk Sees 2025 Gross sales Development of 16% to 24%

Nonetheless, supply constraints and rising competitors are weighing on its outlook. Novo Nordisk projected 2025 gross sales progress of 16% to 24% at fixed alternate charges, beneath the 26% progress it produced in 2024. 

Novo Nordisk stated that the steering displays «intensifying competitors and continued pricing strain inside Diabetes and Weight problems care.» The corporate is a pacesetter within the weight-loss drug space with Mounjaro and Zepbound maker Eli Lilly (LLY).

«In 2025, we’ll proceed our give attention to business execution, on the development of our early and late-stage R&D pipeline and on the growth of our manufacturing capability,» CEO Lars Fruergaard Jorgensen stated.

Novo Nordisk’s U.S.-listed shares have been trending decrease since September, plunging in December after trial outcomes for its weight-loss drug CagriSema upset. The Danish agency stated Wednesday that «so as to safe provide chain readiness,» it plans to file for the primary regulatory approval of CagriSema throughout Q1 2026.